KR20070098798A - Ｄｐｄ 억제제를 5-ｆｕ 및 5-ｆｕ 전구약물과 조합한투여방법 - Google Patents

Ｄｐｄ 억제제를 5-ｆｕ 및 5-ｆｕ 전구약물과 조합한투여방법 Download PDF

Info

Publication number
KR20070098798A
KR20070098798A KR1020077013028A KR20077013028A KR20070098798A KR 20070098798 A KR20070098798 A KR 20070098798A KR 1020077013028 A KR1020077013028 A KR 1020077013028A KR 20077013028 A KR20077013028 A KR 20077013028A KR 20070098798 A KR20070098798 A KR 20070098798A
Authority
KR
South Korea
Prior art keywords
administered
eniluracil
prodrug
dpd inhibitor
dpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077013028A
Other languages
English (en)
Korean (ko)
Inventor
톰 스펙터
윌리암 폴 피터스
도날드 윌리암 커프
브라이언 후버
Original Assignee
애드헤렉스 테크놀로지스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애드헤렉스 테크놀로지스 인크. filed Critical 애드헤렉스 테크놀로지스 인크.
Publication of KR20070098798A publication Critical patent/KR20070098798A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077013028A 2004-12-03 2005-12-05 Ｄｐｄ 억제제를 5-ｆｕ 및 5-ｆｕ 전구약물과 조합한투여방법 Ceased KR20070098798A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63303404P 2004-12-03 2004-12-03
US60/633,034 2004-12-03

Publications (1)

Publication Number Publication Date
KR20070098798A true KR20070098798A (ko) 2007-10-05

Family

ID=36087538

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077013028A Ceased KR20070098798A (ko) 2004-12-03 2005-12-05 Ｄｐｄ 억제제를 5-ｆｕ 및 5-ｆｕ 전구약물과 조합한투여방법

Country Status (10)

Country Link
US (2) US8318756B2 (enExample)
EP (1) EP1827443A1 (enExample)
JP (2) JP2008521930A (enExample)
KR (1) KR20070098798A (enExample)
CN (2) CN101068549A (enExample)
AU (1) AU2005311730B2 (enExample)
CA (1) CA2587514A1 (enExample)
MX (1) MX2007006646A (enExample)
NZ (1) NZ555176A (enExample)
WO (1) WO2006060697A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101068549A (zh) * 2004-12-03 2007-11-07 阿迪赫里克斯技术公司 与5－fu和5－fu前药组合施用dpd抑制剂的方法
US20090196833A1 (en) * 2008-02-06 2009-08-06 Adherex Technologies Inc. Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
WO2009118712A2 (en) * 2008-03-27 2009-10-01 Ecole Polytechnique Federale De Lausanne (Epfl) Novel dihydroxypyrrolidine derivatives as anti-cancer agents
BR112012000873A2 (pt) * 2009-07-17 2019-11-05 Myriad Genetics Inc método de dosar 5-fluorouracil em uma amostra de um paciente tratado com f-fu ou um pró-fármaco deste, método de tratar um paciente com 5-fluorouracil ou um pró-fármaco deste, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste para um teste de 5-fluorouracil, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste, composição, kit, kit de teste, conjunto de seringa de transferência
BR112012008951A2 (pt) 2009-10-14 2019-09-24 Adherex Tech Inc tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd
WO2014089004A1 (en) * 2012-12-04 2014-06-12 Adherex Technologies, Inc. Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
CN106619689B (zh) 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
WO2020125550A1 (zh) * 2018-12-19 2020-06-25 广州君赫生物科技有限公司 化合物在治疗与saicar累积相关的疾病的用途
CN109655606A (zh) * 2019-01-11 2019-04-19 华东师范大学 一种利用3d类器官评价药物肠毒性的检测方法
WO2023283921A1 (zh) * 2021-07-16 2023-01-19 北京深蓝泰医药科技有限公司 Dpd抑制剂及其药物组合物和用途
US20240180910A1 (en) * 2022-12-06 2024-06-06 Elion Oncology, Inc. Method for treating cancer with a chemotherapeutic modifier
US20250017931A1 (en) * 2023-07-13 2025-01-16 Processa Pharmaceuticals, Inc., Methods of personalizing cancer treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629892D0 (en) 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US5157114A (en) 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
EP0539442B1 (en) 1990-07-19 1998-01-07 The Wellcome Foundation Limited Enzyme inactivators
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5476855A (en) 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
NZ330360A (en) 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040028687A1 (en) 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
CN101068549A (zh) * 2004-12-03 2007-11-07 阿迪赫里克斯技术公司 与5－fu和5－fu前药组合施用dpd抑制剂的方法

Also Published As

Publication number Publication date
AU2005311730A1 (en) 2006-06-08
US20130184232A1 (en) 2013-07-18
JP2008521930A (ja) 2008-06-26
WO2006060697A1 (en) 2006-06-08
NZ555176A (en) 2010-03-26
JP2012229273A (ja) 2012-11-22
EP1827443A1 (en) 2007-09-05
CA2587514A1 (en) 2006-06-08
MX2007006646A (es) 2007-11-16
CN101068549A (zh) 2007-11-07
US20060148753A1 (en) 2006-07-06
WO2006060697A9 (en) 2006-09-21
US8318756B2 (en) 2012-11-27
AU2005311730B2 (en) 2011-11-17
CN102441170A (zh) 2012-05-09

Similar Documents

Publication Publication Date Title
US20130184232A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
Álvarez et al. 5-Fluorouracil derivatives: a patent review
Tonkinson et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma
US7812030B2 (en) Methods, compositions, and kits for organ protection during systemic anticancer therapy
CN114727996A (zh) 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
AU2011201504A1 (en) Methods, Compositions, and Kits for Organ Protection During Systemic Anticancer Therapy
JP2020147598A (ja) カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤
JP2016014051A (ja) ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置
AU2012200856B2 (en) Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
US20080255168A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
Beitler et al. Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix
HK1110531A (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
Ramilo-Torno et al. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines
Favier et al. Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer
WO2014089004A1 (en) Methods for treating 5-fluorouracil prodrug non-responsive cancer patients

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070608

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101201

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120830

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130329

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120830

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I